about
The HIV care cascade: a systematic review of data sources, methodology and comparabilityActivation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyTime from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: Dramatic fall from 2011 to 2015Poverty, hunger, education, and residential status impact survival in HIV.Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review.Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring.Repeated assessments of food security predict CD4 change in the setting of antiretroviral therapy.Experiences and expectations of participants completing an HIV cure focused clinical trial.Clinic Network Collaboration and Patient Tracing to Maximize Retention in HIV CareRisk factors for mortality during antiretroviral therapy in older populations in resource-limited settings.Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.A longitudinal cohort study of HIV 'treatment as prevention' in gay, bisexual and other men who have sex with men: the Treatment with Antiretrovirals and their Impact on Positive And Negative men (TAIPAN) study protocol.Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, IndiaRisk factors for unstructured treatment interruptions and association with survival in low to middle income countriesBroad activation of latent HIV-1 in vivo.Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome.Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy.Less frequent CD4 monitoring in virologically suppressed HIV.No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.Integrase-resistant HIV in an antiretroviral-naive patient in Australia.90-90-90: how do we get there?Paying the price in an era of HIV treatment as prevention: a retrospective study of the cost burden of HIV treatment for people living with HIV in Victoria, Australia.Targets for intervention to improve virological outcomes for patients receiving free antiretroviral therapy in Tamil Nadu, India.Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy.Yoghurt consumption and damaged colonic mucosa: A case of Lactococcus lactis liver abscess in an immunocompetent patientThe effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trialRoutine versus Targeted Viral Load Strategy among Patients Starting Antiretroviral in Hanoi, VietnamDiverse effects of interferon alpha on the establishment and reversal of HIV latency
P50
Q26775579-A97DC7BA-991F-41BA-A7C5-DFF5AE0D413BQ28544949-3D61A1DF-56A3-42B5-BED1-4A68F4F46BB9Q33693810-886ED300-3425-40F3-B413-1F3847307521Q34441490-25B9C527-3F0D-4742-A9D3-18ED7B190279Q34592711-85822A14-267E-4E89-A799-780252AA37C8Q34699180-EA163FEE-F23F-455E-8EE5-8E4084C232CAQ35175836-0F00C739-876D-42C7-98C2-BFE9D2A03821Q35471789-E451CCA8-C9CF-4CA5-B411-1C6C0DED9F01Q35641804-ECB4E020-CF54-4999-95A2-0961B6330698Q35897165-DDBACC5B-3FCA-42C2-8084-75230C0E2DA6Q35917578-BF2B7961-026A-45F0-8FD3-FD55E29198C7Q36141252-69274250-5A8B-47F7-BB30-0AD873F96E83Q36220750-9D4FD6AF-E577-46AB-8F88-AFC5AC4EB812Q36906379-D197D8D9-688A-49A2-81B6-2AD69A3F8842Q37085020-21DD2E3D-E80E-4FCC-958C-7662F10E271CQ37260309-4694F1BA-8BF3-4EBB-BF4E-8113D51F5D2DQ37413059-25D08729-3A2B-4F03-A66A-B853FF26A2EFQ40198241-75FA752A-900E-4A90-AE49-3A955517342CQ40217724-6D5CD812-67CA-44E1-A3E2-A62DA83EA320Q40250277-8014A277-F930-4C52-AEC3-1112D79B7E0FQ40289284-3E788482-42DA-4195-9B01-0E8B5F3A33AEQ40359982-E110F0BB-EDD4-4A43-90C8-6729C461169FQ40972572-927C5079-2359-48E2-B434-D6F99C1146B0Q41664338-A240483D-CFDA-47EA-A7BA-99DC45C87697Q42244267-E4522B61-9871-4F09-AE04-C6408F8120A6Q47135424-BDB6B6E4-B9B1-4CD6-87AD-360C88283497Q57240626-6EEA57B4-64FC-4190-8572-C7B54E5A6279Q58003760-4781BA11-6687-4A75-86FE-9E484925E32EQ64066142-8538D4DC-86A4-4A61-AE6D-FA92FFF78FFBQ89935915-4DDBEF95-B7C4-4A79-AB30-6E0AACED35E6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
James H McMahon
@ast
James H McMahon
@en
James H McMahon
@es
James H McMahon
@nl
type
label
James H McMahon
@ast
James H McMahon
@en
James H McMahon
@es
James H McMahon
@nl
prefLabel
James H McMahon
@ast
James H McMahon
@en
James H McMahon
@es
James H McMahon
@nl
P108
P106
P21
P31
P496
0000-0003-1460-5572